Kennebec Savings Bank Acquires Shares of 3,300 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Kennebec Savings Bank purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $103,000.

Several other institutional investors have also recently added to or reduced their stakes in SUPN. Los Angeles Capital Management LLC bought a new stake in Supernus Pharmaceuticals in the third quarter valued at about $625,000. State of New Jersey Common Pension Fund D bought a new position in Supernus Pharmaceuticals during the third quarter worth $1,774,000. Meritage Portfolio Management increased its stake in Supernus Pharmaceuticals by 10.8% during the third quarter. Meritage Portfolio Management now owns 44,295 shares of the specialty pharmaceutical company’s stock valued at $1,381,000 after purchasing an additional 4,328 shares during the last quarter. Assetmark Inc. lifted its position in shares of Supernus Pharmaceuticals by 2.8% in the 3rd quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after buying an additional 908 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Supernus Pharmaceuticals by 5.4% during the 3rd quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company’s stock valued at $8,899,000 after buying an additional 14,566 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $36.60 on Monday. The company has a 50 day moving average price of $33.13 and a 200 day moving average price of $30.68. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of 34.21 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a 52 week low of $24.46 and a 52 week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business’s quarterly revenue was up 14.2% on a year-over-year basis. During the same period last year, the business earned ($0.29) EPS. Equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Georges Gemayel sold 14,213 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the transaction, the director now owns 13,315 shares in the company, valued at $487,595.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on SUPN shares. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.